168 related articles for article (PubMed ID: 30973373)
1. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
Shah HA; Fischer JH; Venepalli NK; Danciu OC; Christian S; Russell MJ; Liu LC; Zacny JP; Dudek AZ
Am J Clin Oncol; 2019 May; 42(5):413-420. PubMed ID: 30973373
[TBL] [Abstract][Full Text] [Related]
2. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
[TBL] [Abstract][Full Text] [Related]
3. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
Semrad TJ; Kim EJ; Gong IY; Li T; Christensen S; Arora M; Riess JW; Gandara DR; Kelly K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):335-341. PubMed ID: 33993383
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
Zhou X; Mould DR; Yuan Y; Fox E; Greengard E; Faller DV; Venkatakrishnan K
J Clin Pharmacol; 2022 Feb; 62(2):206-219. PubMed ID: 34435684
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
13. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
[TBL] [Abstract][Full Text] [Related]
16. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Zhou X; Nemunaitis J; Pant S; Bauer TM; Patel M; Sarantopoulos J; Craig Lockhart A; Goodman D; Huebner D; Mould DR; Venkatakrishnan K
Invest New Drugs; 2018 Apr; 36(2):240-247. PubMed ID: 28819760
[TBL] [Abstract][Full Text] [Related]
17. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
Mossé YP; Lipsitz E; Fox E; Teachey DT; Maris JM; Weigel B; Adamson PC; Ingle MA; Ahern CH; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6058-64. PubMed ID: 22988055
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
19. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
20. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
Zhou X; Mould DR; Takubo T; Sheldon-Waniga E; Huebner D; Milton A; Venkatakrishnan K
Br J Clin Pharmacol; 2018 Jan; 84(1):35-51. PubMed ID: 28891222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
